Moloney Securities Asset Management LLC Buys 12,530 Shares of Novo Nordisk A/S $NVO

Moloney Securities Asset Management LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 112.2% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,699 shares of the company’s stock after purchasing an additional 12,530 shares during the period. Moloney Securities Asset Management LLC’s holdings in Novo Nordisk A/S were worth $1,315,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Capital Investment Advisory Services LLC grew its holdings in Novo Nordisk A/S by 2.7% during the third quarter. Capital Investment Advisory Services LLC now owns 10,853 shares of the company’s stock valued at $602,000 after purchasing an additional 281 shares during the period. Bond & Devick Financial Network Inc. lifted its holdings in Novo Nordisk A/S by 2.4% in the 3rd quarter. Bond & Devick Financial Network Inc. now owns 14,872 shares of the company’s stock worth $825,000 after purchasing an additional 350 shares in the last quarter. Portside Wealth Group LLC lifted its holdings in shares of Novo Nordisk A/S by 18.4% in the third quarter. Portside Wealth Group LLC now owns 49,415 shares of the company’s stock worth $2,742,000 after buying an additional 7,677 shares in the last quarter. HighPoint Advisor Group LLC lifted its stake in Novo Nordisk A/S by 2.6% in the 3rd quarter. HighPoint Advisor Group LLC now owns 19,914 shares of the company’s stock worth $1,105,000 after purchasing an additional 503 shares in the last quarter. Finally, SBI Securities Co. Ltd. lifted its position in shares of Novo Nordisk A/S by 73.6% in the third quarter. SBI Securities Co. Ltd. now owns 24,884 shares of the company’s stock worth $1,381,000 after buying an additional 10,548 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 10.1%

Novo Nordisk A/S stock opened at $47.71 on Friday. The firm has a market cap of $213.03 billion, a price-to-earnings ratio of 13.75 and a beta of 0.67. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $93.80. The business’s 50-day moving average price is $53.61 and its 200 day moving average price is $53.85. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, February 4th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is currently 23.63%.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA says it will target mass-marketed, unapproved compounded drug copies, which reduces the competitive threat from low-cost copycats and helped lift sentiment. Novo Nordisk shares rebound as FDA targets illegal drug copies – Reuters
• Positive Sentiment: Some analysts view the recent selloff as overdone and argue NVO’s strong cash flow, first-mover Wegovy advantages and promising pipeline (CagriSema) make the pullback a buying opportunity for long-term holders. Novo Nordisk: The Selloff Is A Blessing In Disguise – Seeking Alpha
• Positive Sentiment: Novo has announced it will pursue legal action against Hims & Hers over compounded Wegovy copies — a defensive step that could limit spread of low-cost alternatives if successful. Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding – Reuters
• Neutral Sentiment: Company disclosure shows trading by board members and executives — useful for monitoring insider behavior but not immediately directional. Trading in Novo Nordisk shares by board members, executives – GlobeNewswire
• Neutral Sentiment: Company declared a dividend (record/ex-dividend dates published) — supportive for income investors but not a cure for near-term volume/price headwinds.
• Negative Sentiment: Hims & Hers launched a $49–$99 compounded oral semaglutide offering, sharply undercutting Wegovy’s price and triggering market panic about pricing erosion and access to cheap compounding alternatives. Hims and Hers Health launches copy of Wegovy pill at $49 – Reuters
• Negative Sentiment: Citi warns that inability to curb compounded semaglutide use is a lingering risk to Novo’s pricing power and investor sentiment. Citi flags lingering risks to Novo despite strong weight-loss portfolio – Proactive Investors
• Negative Sentiment: Competitive dynamics: Eli Lilly’s strong guidance and manufacturing scale are shifting market share and investor preference toward Lilly, increasing near-term pressure on Novo’s revenue outlook. The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles – MarketBeat
• Negative Sentiment: Regional weakness: Ozempic sales in greater China fell for the first time, highlighting geographic and competitive pressures. Novo reports first Ozempic sales drop in greater China region – Reuters

Analyst Ratings Changes

Several brokerages recently weighed in on NVO. Morgan Stanley restated an “underweight” rating and issued a $42.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. TD Cowen reissued a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, January 9th. Finally, Citigroup began coverage on Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Seven analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $56.07.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.